icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
SHtCVYgjgPWmeAGk
Listen
